A letter to the editor is presented in response to the article on the Gardos channel inhibitor senicapoc which was proven on a Phase II clinical trial to diminish hemolytic anaemia in adults with sickle cell anaemia by K.I. Ataga, W.R. Smith, L.M. De Castro in the 2008 issue.